Beta Bionics faces a class action lawsuit alleging it misled investors about the safety and regulatory status of its iLet Bionic Pancreas insulin pump. The lawsuit claims the company downplayed FDA concerns related to its manufacturing quality and failure to report serious injuries, which led to a stock price decline. Investors who bought Beta Bionics securities between July 30, 2025, and February 24, 2026, may be eligible to join the suit. The deadline to apply as lead plaintiff is November 3, 2026.
UBS increased its price target for ABM Industries to $51.50 following the company's strong quarterly earnings and revenue growth. ABM reported a 4.2% revenue increase to $2.32 billion and a 19% rise in net income to $49.7 million, alongside strong ca...
Chewy reported quarterly earnings of $0.36 per share, doubling analyst estimates of $0.18, with net income rising to $80.5 million from $62 million a year ago. Quarterly revenue reached $3.33 billion, slightly above expectations, marking a 7.3% incre...
AeroVironment, a leading drone maker, is set to report its Q3 earnings on September 9, 2026, with analysts expecting EPS between $0.22 and $0.25 and revenue near $452-$456 million. The company recently secured major contracts worth over $865 million ...
Bernstein has reduced the price target for Newmont Corporation to $144, reflecting challenges including a 13% drop in gold production and rising costs expected to reach $1,680 per ounce in 2026. Despite these issues, Newmont's stock gained 34.5% in A...
Barrick Mining maintains an 'Outperform' rating from Bernstein despite a lowered price target of $56.50, down from $61.00. The company reported an 11% increase in gold production in Q2 to 796,000 ounces, with further growth expected in the coming qua...
